Palopegteriparatide: New Hormone Replacement Therapy for Chronic Hypoparathyroidism in Adults
Palopegteriparatide has emerged as a significant development in the management of chronic hypoparathyroidism, a rare endocrine disorder characterized by insufficient parathyroid hormone (PTH) production. Following recent regulatory approvals, this once-daily subcutaneous injection offers a targeted replacement therapy for adults struggling to maintain stable calcium and phosphate levels through conventional treatments. As a physician, I have … Read more